ID   PCI-30
AC   CVCL_C757
SY   PCI30
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 1049
DR   Cell_Model_Passport; SIDM00044
DR   Cosmic-CLP; 1298529
DR   DepMap; ACH-002295
DR   EGA; EGAS00001000978
DR   GDSC; 1298529
DR   GEO; GSM937840
DR   GEO; GSM937841
DR   GEO; GSM1670342
DR   PharmacoDB; PCI30_1251_2019
DR   PRIDE; PXD030304
DR   Wikidata; Q54938687
RX   PubMed=8084624;
RX   PubMed=17312569;
RX   PubMed=20215515;
RX   PubMed=23419152;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro153Alafs*28 (c.455dupC) (c.455_456insC) (p.P152fs) (c.459_460insC); ClinVar=VCV000182958; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0.38%; Native American=0%; East Asian, North=0.85%; East Asian, South=0.5%; South Asian=4.81%; European, North=42.64%; European, South=50.82% (PubMed=30894373).
ST   Source(s): Cosmic-CLP
ST   Amelogenin: X,Y
ST   CSF1PO: 10
ST   D13S317: 13
ST   D16S539: 12,13
ST   D5S818: 11,12
ST   D7S820: 10,12
ST   TH01: 6
ST   TPOX: 10,11
ST   vWA: 14,17
DI   NCIt; C4648; Tongue squamous cell carcinoma
DI   ORDO; Orphanet_457252; Squamous cell carcinoma of the oral tongue
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   54Y
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 30-01-24; Version: 24
//
RX   PubMed=8084624; DOI=10.1177/01945998941113P105;
RA   Snyderman C.H., Klapan I., Milanovich M., Heo D.S., Wagner R.,
RA   Schwartz D.R., Johnson J.T., Whiteside T.L.;
RT   "Comparison of in vivo and in vitro prostaglandin E2 production by
RT   squamous cell carcinoma of the head and neck.";
RL   Otolaryngol. Head Neck Surg. 111:189-196(1994).
//
RX   PubMed=17312569; DOI=10.1002/hed.20478;
RA   Lin C.J., Grandis J.R., Carey T.E., Gollin S.M., Whiteside T.L.,
RA   Koch W.M., Ferris R.L., Lai S.Y.;
RT   "Head and neck squamous cell carcinoma cell lines: established models
RT   and rationale for selection.";
RL   Head Neck 29:163-188(2007).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=23419152; DOI=10.1186/gm419;
RA   Lechner M., Fenton T., West J., Wilson G., Feber A., Henderson S.,
RA   Thirlwell C., Dibra H.K., Jay A., Butcher L.M., Chakravarthy A.R.,
RA   Gratrix F., Patel N., Vaz F., O'Flynn P., Kalavrezos N.,
RA   Teschendorff A.E., Boshoff C., Beck S.;
RT   "Identification and functional validation of HPV-mediated
RT   hypermethylation in head and neck squamous cell carcinoma.";
RL   Genome Med. 5:15.1-15.16(2013).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//